ViRexx works with Canadian biodefense agency to expand Chimigen platform

By Elaine Rigoli

Tampa, Fla., March 31 - ViRexx Medical Corp. has entered into a research collaboration with Defence Research and Development Canada - Suffield to evaluate the use of the Chimigen vaccine platform for biodefense applications.

ViRexx has used the Chimigen platform to develop HepaVaxx B as a therapeutic vaccine candidate to treat chronic hepatitis B infection, according to a news release.

There are roughly 370 million chronic carriers of hepatitis B worldwide and there is no therapeutic vaccine available in the market at present, the company said.

ViRexx said it has filed a clinical trial application with Health Canada for HepaVaxx B and expects to begin a phase 1 trial during the first half of 2006.

The company is also conducting preclinical studies on Chimigen therapeutic vaccine candidates to treat chronic hepatitis C infections.

ViRexx is an Edmonton, Alta.-based biotechnology company focused on the development of therapeutic products for the treatment of certain cancers and specified chronic viral infections.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.